T. Šálek
The frontline setting patients with ovarian cancer has potential to change shortly,
with targeted and immunotherapy strategies showing promising signals of activity.
Such combined approaches in the first-line setting include chemotherapy plus
the PD-1 inhibitor pembrolizumab (Keytruda) followed by pembrolizumab maintenance.
The addition of PARP inhibitors in the frontline setting is promising. In October
2017, the FDA accepted a supplemental biologics license application for bevacizumab,
in combination with carboplatin and paclitaxel, followed by bevacizumab
alone, for the first-line treatment of advanced epithelial ovarian, fallopian tube, or
primary peritoneal cancer. Certainly, in some cancer types, we are moving to immunotherapy
as a frontline setting and hopefully for patients with ovarian cancer that
will be an option — but we are not there yet.